BioMarin paid over $5 Billion for Kyndrisa and you are saying it is still a huge buy "even without" it ? Whatever you are smoking must be really good. The company is expecting over $1 billion in peak for this drug. Any setback or delay will tank the share like CLVS today, maybe not that dramtic.
"What I can tell you is even without Kyndrisa, BMRN still is a huge buy since they have several other drugs in the pipeline just as big".
I disagree with your comments above. A lot is riding on this drug. Total company revenue today is less than $1 Billion, BMRN is projecting over $1 Billion in revenue ALONE from this drug. Any setback, and the stock will drop 20% to 30% in a blink of an eye, at the same time if FDA panel recommends approving this drug, stock will pop 20% to 30%.
If you are long, my advise to you is to hedge with some Puts. I don't have any position right now but will buy once I free up my cash from FB and PCLN next week.